...360 and 480 mg oral NPT200-11 were well tolerated. UCB has exclusive, worldwide rights to NPT200-11... ...Neuropore Therapies Inc. , San Diego, Calif. UCB Group (Euronext:UCB), Brussels, Belgium Product: UCB1332 , NPT200-11...
No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
...Unterach, Austria), granted UCB Group (Euronext:UCB) an exclusive, worldwide license to preclinical Parkinson's disease candidate NPT200-11... ...up to $460 in development, regulatory and sales milestones, plus royalties. The companies will co-develop NPT200-11...
